Hepatocellular carcinoma and antidepressants: a nationwide population-based study

Hepatocellular carcinoma (HCC) is highly prevalent in Asia. Antidepressants have been associated with increase in hepatocellular carcinoma. This is the first Asian population-based study to evaluate the association between antidepressant use and risk of HCC. Based on Taiwan's National Health In...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2017-05, Vol.8 (18), p.30464-30470
Main Authors: Chen, Vincent Chin-Hung, Lin, Chiao-Fan, Hsieh, Yi-Hsuan, Liang, Hsin-Yi, Huang, Kuo-You, Chiu, Wei-Che, Lee, Yena, McIntyre, Roger S, Chan, Hsiang-Lin
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antidepressive Agents - adverse effects
Carcinoma, Hepatocellular - epidemiology
Carcinoma, Hepatocellular - etiology
Case-Control Studies
Clinical Research Paper
Humans
Liver Neoplasms - epidemiology
Liver Neoplasms - etiology
Middle Aged
Odds Ratio
Population Surveillance
Socioeconomic Factors
Taiwan - epidemiology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatocellular carcinoma (HCC) is highly prevalent in Asia. Antidepressants have been associated with increase in hepatocellular carcinoma. This is the first Asian population-based study to evaluate the association between antidepressant use and risk of HCC. Based on Taiwan's National Health Insurance Research Database, we conducted a nationwide population-based study. A total of 49,998 cases with HCC were identified and paired with 244,236 randomly selected controls. The data was analyzed via the conditional logistic regression model adjusting for several confounding factors. Use of tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) was associated with lower risk for HCC. No apparent association was found between use of other classes of antidepressants and HCC, including monoamine oxidase inhibitors (MAOIs), serotonin norepinephrine reuptake inhibitors (SNRIs), trazodone, mirtazapine and bupropion. The findings of a protective effect of TCAs and SSRIs for HCC should be interpreted with caution and warrants further research.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.12826